FDA approval date:
BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients
with mantle cell lymphoma (MCL) who have received at least one prior
Mechanism of Action:
Zanubrutinib is a small-molecule inhibitor of BTK. Zanubrutinib forms a covalent bond with a
cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signaling
molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK
signaling results in activation of pathways necessary for B-cell proliferation, trafficking,
chemotaxis, and adhesion. In nonclinical studies, zanubrutinib inhibited malignant B-cell
proliferation and reduced tumor growth.
Capsules: 80 mg.
The most common adverse reactions (≥ 20%) included neutrophil count
decreased, platelet count decreased, upper respiratory tract infection, white
blood cell count decreased, hemoglobin decreased, rash, bruising, diarrhea